An immunostimulant nanomedicine enhances radioimmunotherapy by remodeling the tumor immunosuppressive landscape after radiotherapy.

Mengwan Jiang, Mingyue Chen, Wen Zou, Yingxin Xie, Jinjin Shi, Junjie Liu, Aibing Chen, Xiu Zhao

Abstract read

In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mengwan JiangSchool of Artificial Intelligence and Big Data, Henan University of Technology, Zhengzhou 450001, China.

Mingyue ChenCollege of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, China.

Wen ZouSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.

Yingxin XieSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.

Jinjin ShiSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.

Junjie LiuSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.

Aibing ChenCollege of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, China.

Xiu ZhaoSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Studies have shown that radiotherapy (RT) has powerful immune-stimulating effects. However, RT-mediated distal tumor regression is rare in clinical practice. Here, with an animal experimental model, we found that RT shaped an immunosuppressive landscape characterized by a high-influx of myeloid-derived suppressor cells (MDSCs), and the induction of immunologically silent tumor apoptosis, hindering the efficacy of radioimmunotherapy. To address this issue, we developed a spatiotemporally controlled nanomedicine for remodeling the immunosuppressive tumor microenvironment (TME) post-RT. Decitabine (DAC)-loaded ferritin (Ft) were crosslinked

Indexed as

ApoptosisBreast cancerImmune landscapeMyeloid-derived suppressor cellsNanomedicinePyroptosisRadiotherapyTumor microenvironment

Identifiers

PMID41685155

DOI10.1016/j.apsb.2025.11.012

PMCPMC12891846

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.